At the MMRF, collaboration is not just a priority; it is the only way we do things. We work closely with the best partners in the biotech and pharmaceutical industries, academia, and the cancer community to inject speed and efficiency into the process of discovering and developing new drugs for the treatment of multiple myeloma.
The MMRF is the only organization that has built an end-to-end cancer research system that drives drug discovery and accelerates treatments to patients. It unites industry, academia, researchers, biotechs, clinics, the FDA, the NIH, caregivers and patients. This unique model is being emulated for other disease research and is comprised of three interrelated parts.
A robust collection of high quality clinical and molecular data that makes it possible for the global research community to work as one.
This first-of-its-kind study will provide one of the most comprehensive clinical genome maps of any cancer leading to a better understanding of disease progression and greater insights for the development of personalized treatments.READ MORE
The molecular profiles of 500 relapsed and refractory patients will help us accelerate development of targeted therapies for different subtypes of myeloma.READ MORE
This registry will allow health care professionals and researchers to identify trends, learn about the most effective treatments and design clinical trials for potential new therapies.READ MORE
Open sharing of our valuable data allows researchers and clinicians worldwide to contribute to a growing knowledge base, accelerating one another’s research and discovery. Learn more.
This first-in-class publicly shared database provides access to genomic data from the landmark MMRF CoMMpass Study℠. The Gateway is available to researchers and clinicians.READ MORE
Integrative analyses of the genomic and clinical data generated by the MMGI and the landmark MMRF CoMMpass Study℠ will help accelerate more effective treatment approaches for all patients.READ MORE
Findings uncovered at the basic science level are brought to the clinic where they can directly benefit patients.READ MORE
Our own clinical network of leading research institutions and cancer centers, the Multiple Myeloma Research Consortium, helps speed new therapies to trial and to the patients that need them. Learn more.
The Multiple Myeloma Research Consortium, the clinical research arm of the MMRF, is a collaborative network of 22 leading academic and community centers that conduct research and clinical trials.READ MORE
The MMRF has helped to bring a record ten drugs to market in the time it normally takes to get one drug approved.READ MORE
The MMRC has built one of the most robust and balanced clinical trial portfolios for myeloma patients.READ MORE
The MMRF provides Continuing Medical Education (CME) accredited programs for healthcare professionals to learn more about multiple myeloma, emerging treatment options and clinical trials from key leaders in myeloma.
Multiple Myeloma Virtual Institute - Personalizing Multiple Myeloma Treatment for Maximum Benefit Case-based Activity
Multiple Myeloma Updates from the 20th EHA Congress and 2015 ASCO Annual Meeting
Multiple Myeloma Updates from the 2014 ASH Annual Meeting
Together with our partners, the MMRF has opened more than 60 trials of 30 new therapies including immunotherapies, targeted therapies and novel agents that have the potential to improve and extend the lives of myeloma patients.SEE CURRENT TRIALS